No Data
Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board With Appointments of World Class Veterans
CDC Warns Against a Spike in COVID, Flu Cases
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study
Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?
The phase III study of glaxosmithkline (GSK.US) IBAT inhibitor for the treatment of PBC-related cholestatic pruritus was successful.
On November 19, glaxosmithkline (GSK.US) announced that the Phase III GLISTEN study has achieved positive results.
GSK Says Trial of Itch Treatment Linerixibat Meets Primary Endpoint
No Data
No Data
